- An affiliate of Aterian Investment Partners has agreed to recapitalise Contract Pharmaceuticals Limited Canada (CPL), a North American contract development and manufacturing organisation (CDMO) of non-sterile liquid and semi-solid dosage forms.
- CPL, based in Mississauga, Ontario, Canada, has longstanding relationships with 15 of the top 20 global pharmaceutical companies.
- The proposed recapitalisation is subject to the approval of the Ontario Superior Court of Justice (Commercial List).
An affiliate of Aterian Investment Partners, a private investment firm, has agreed to recapitalise Contract Pharmaceuticals Limited Canada (CPL), a North American contract development and manufacturing organisation (CDMO) of non-sterile liquid and semi-solid dosage forms.
CPL is based in Mississauga, Ontario, Canada, and supports its customers through its FDA and Health Canada-registered facilities, selling into North America, the European Union, Japan, Australia, Mexico, Brazil, and the Middle East.
Christopher H. Thomas, Co-Founder & Partner at Aterian, stated, “CPL is a North American market leader in developing prescription-based products in its categories for some of the most trusted pharmaceutical companies in the world. We will continue building on these partnerships and investing behind the CPL management team, product development, and production and manufacturing capabilities.”
The proposed recapitalization is subject to the approval of the Ontario Superior Court of Justice (Commercial List). With Aterian’s support, CPL plans to make continued investments in innovation, capabilities, and capacity development. Jan Sahai, CEO of CPL, expressed excitement about entering this new chapter with Aterian, which has a demonstrated history of supporting companies with a focus on product innovation and partnership. He also acknowledged the absolute dedication of CPL employees during this process to continue to develop and manufacture products so many patients are depending on.
